WO2004106934A3 - Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7) - Google Patents

Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7) Download PDF

Info

Publication number
WO2004106934A3
WO2004106934A3 PCT/EP2004/005255 EP2004005255W WO2004106934A3 WO 2004106934 A3 WO2004106934 A3 WO 2004106934A3 EP 2004005255 W EP2004005255 W EP 2004005255W WO 2004106934 A3 WO2004106934 A3 WO 2004106934A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
hydroxytryptamine
serotonin
therapeutics
Prior art date
Application number
PCT/EP2004/005255
Other languages
French (fr)
Other versions
WO2004106934A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Priority to EP04733262A priority Critical patent/EP1634081A2/en
Priority to US10/558,297 priority patent/US20070128603A1/en
Publication of WO2004106934A2 publication Critical patent/WO2004106934A2/en
Publication of WO2004106934A3 publication Critical patent/WO2004106934A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Abstract

The invention provides a human 5-HT7 which is associated with the cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, dermatological disorders, gastrointestinal and liver diseases, cancer disorders, inflammatory diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of 5-HT7 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2004/005255 2003-05-28 2004-05-15 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7) WO2004106934A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04733262A EP1634081A2 (en) 2003-05-28 2004-05-15 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
US10/558,297 US20070128603A1 (en) 2003-05-28 2004-05-15 Diagnostic and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011961.4 2003-05-28
EP03011961 2003-05-28

Publications (2)

Publication Number Publication Date
WO2004106934A2 WO2004106934A2 (en) 2004-12-09
WO2004106934A3 true WO2004106934A3 (en) 2005-05-19

Family

ID=33483893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/005255 WO2004106934A2 (en) 2003-05-28 2004-05-15 Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)

Country Status (3)

Country Link
US (1) US20070128603A1 (en)
EP (1) EP1634081A2 (en)
WO (1) WO2004106934A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1875899A1 (en) * 2006-06-29 2008-01-09 Laboratorios Del Dr. Esteve, S.A. Use of 5HT7 receptor agonists for the treatment of pain
EP2676954A1 (en) 2012-06-19 2013-12-25 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-phenyl derivatives as vasodilators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766879A (en) * 1992-12-24 1998-06-16 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4 serotonin receptors and uses thereof
US5985585A (en) * 1992-11-03 1999-11-16 Synaptic Pharmaceutical Coorporation Processes using a human serotonin receptor (5-HT4B)
WO2000077199A1 (en) * 1999-06-14 2000-12-21 Janssen Pharmaceutica N.V. Cloning and expression of a novel 5-ht4 receptor
US6300087B1 (en) * 1992-11-03 2001-10-09 Synaptic Pharmaceutical Corporation DNA encoding a human serotonin receptor (5-HT4B) and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976813A (en) * 1997-12-12 1999-11-02 Abbott Laboratories Continuous format high throughput screening
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US6432974B1 (en) * 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
EP1334130A2 (en) * 2000-10-31 2003-08-13 Bayer Ag Regulation of human serotonin receptor precursor
WO2003014321A2 (en) * 2001-08-10 2003-02-20 The Rockefeller University Compositions and methods for modulation of darpp-32 phosphorylation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985585A (en) * 1992-11-03 1999-11-16 Synaptic Pharmaceutical Coorporation Processes using a human serotonin receptor (5-HT4B)
US6300087B1 (en) * 1992-11-03 2001-10-09 Synaptic Pharmaceutical Corporation DNA encoding a human serotonin receptor (5-HT4B) and uses thereof
US6376243B1 (en) * 1992-11-03 2002-04-23 Synaptic Pharmaceutical Corporation DNA encoding a human serotonin receptor (5-HT4b) and uses thereof
US5766879A (en) * 1992-12-24 1998-06-16 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4 serotonin receptors and uses thereof
US6331401B1 (en) * 1992-12-24 2001-12-18 Synaptic Pharmaceutical Corporation Uses of the 5-HT4 receptor
WO2000077199A1 (en) * 1999-06-14 2000-12-21 Janssen Pharmaceutica N.V. Cloning and expression of a novel 5-ht4 receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KROBERT KURT A ET AL: "The human 5-HT7 serotonin receptor splice variants: Constitutive activity and inverse agonist effects", BRITISH JOURNAL OF PHARMACOLOGY, vol. 135, no. 6, March 2002 (2002-03-01), pages 1563 - 1571, XP002300036, ISSN: 0007-1188 *

Also Published As

Publication number Publication date
US20070128603A1 (en) 2007-06-07
WO2004106934A2 (en) 2004-12-09
EP1634081A2 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2005095973A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005103702A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 2 (cxcr2)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004082568A3 (en) Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005103711A3 (en) Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1)
WO2004082571A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86)
WO2005040824A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004733262

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004733262

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007128603

Country of ref document: US

Ref document number: 10558297

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10558297

Country of ref document: US